[1] Sharma A, Sharma KL, Gupta A, et al.Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update[J]. World J Gastroenterol,2017,23(22):3978-3998.
[2] 张明迪, 龚伟, 郑莹, 等. 上海市胆囊癌流行状况和趋势分析[J]. 中国实用外科杂志,2013,33(8):691-694.
[3] 邹珍, 鲍萍萍, 吴春晓, 等. 上海市人群2004—2008年胆囊癌生存率分析[J]. 上海预防医学,2018,30(7):569-573,583.
[4] Butte JM, Gonen M, Allen PJ, et al.The role of laparoscopic staging in patients with incidental gallbladder cancer[J]. HPB (Oxford),2011,13(7):463-472.
[5] Bridgewater JA, Goodman KA, Kalyan A, et al.Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling[J]. Am Soc Clin Oncol Educ Book,2016,35:e194-e203.
[6] 安宏建, 朱金荣, 包焰峰. 腹腔镜与开腹手术相关意外胆囊癌临床对比分析[J]. 中国现代手术学杂志,2015, 19(5):343-346.
[7] 刘恩菊, 高玉堂, 邓杰, 等. 既往疾病史和胆道癌关系的全人群病例对照研究[J]. 肿瘤,2002,22(6):453-456.
[8] Benson AR 3rd, D'Angelica MI, Abbott DE, et al. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017[J]. J Natl Compr Canc Netw,2017,15(5):563-573.
[9] Lee H, Kwon W, Han Y, et al.Optimal extent of surgery for early gallbladder cancer with regard to long-term survival: a meta-analysis[J]. J Hepatobiliary Pancreat Sci,2018,25(2):131-141.
[10] Jang JY, Heo JS, Han Y, et al.Impact of type of surgery on survival outcome in patients with early gallbladder cancer in the era of minimally invasive surgery: oncologic safety of laparoscopic surgery[J]. Medicine (Baltimore),2016,95(22):e3675.
[11] Kim HS, Park JW, Kim H, et al.Optimal surgical treatment in patients with T1b gallbladder cancer: An international multicenter study[J]. J Hepatobiliary Pancreat Sci,2018,25(12):533-543.
[12] Goetze TO, Paolucci V. Immediate radical re-resection of incidental T1b gallbladder cancer and the problem of an adequate extent of resection (results of the German Re-gistry “Incidental Gallbladder Cancer”)[J]. Zentralbl Chir,2014,139 Suppl 2:e43-e48.
[13] Lee SE, Kim SW, Han HS, et al.Surgical strategy for T2 gallbladder cancer: nationwide multicenter survey in Korea[J]. J Korean Med Sci,2018,33(28):e186.
[14] D'Hondt M, Lapointe R, Benamira Z, et al. Carcinoma of the gallbladder: patterns of presentation, prognostic factors and survival rate. An 11-year single centre expe-rience[J]. Eur J Surg Oncol,2013,39(6):548-553.
[15] Hickman L, Contreras C.Gallbladder cancer: diagnosis, surgical management, and adjuvant therapies[J]. Surg Clin North Am,2019,99(2):337-355.
[16] Ethun CG, Postlewait LM, Le N, et al.Association of optimal time interval to re-resection for incidental gallbladder cancer with overall survival: A multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium[J]. JAMA Surg,2017,152(2):143-149.
[17] Rathanaswamy S, Misra S, Kumar V, et al.Incidentally detected gallbladder cancer- the controversies and algorithmic approach to management[J]. Indian J Surg,2012, 74(3):248-254.
[18] de Aretxabala X, Oppliger F, Solano N, et al. Laparoscopic management of incidental gallbladder cancer[J]. Surg Endosc,2018,32(10):4251-4255.
[19] Hundal R, Shaffer EA.Gallbladder cancer: epidemiology and outcome[J]. Clin Epidemiol,2014,6:99-109.
[20] Lee HY, Kim YH, Jung GJ, et al.Prognostic factors for gallbladder cancer in the laparoscopy era[J]. J Korean Surg Soc,2012,83(4):227-236.
[21] Ethun CG, Postlewait LM, Le N, et al.Routine port-site excision in incidentally discovered gallbladder cancer is not associated with improved survival: A multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium[J]. J Surg Oncol,2017,115(7):805-811.
[22] Tsujita E, Ikeda Y, Kinjo N, et al.Late-type port-site recurrence of unexpected gallbladder carcinoma 11 years after laparoscopic cholecystectomy[J]. Asian J Endosc Surg,2014,7(4):304-307.
[23] 李斌, 刘辰, 姜小清. 胆囊癌规范化诊治专家共识(2016)[J]. 临床肝胆病杂志,2017,33(4):611-620.
[24] Goetze TO, Paolucci V.The prognostic impact of positive lymph nodes in stages T1 to T3 incidental gallbladder carcinoma: results of the German Registry[J]. Surg Endosc,2012,26(5):1382-1389.
[25] Kishi Y, Nara S, Esaki M, et al.Extent of lymph node dissection in patients with gallbladder cancer[J]. Br J Surg,2018,105(12):1658-1664.
[26] Vega EA, Vinuela E, Yamashita S, et al.Extended lymphadenectomy is required for incidental gallbladder cancer independent of cystic duct lymph node status[J]. J Gastrointest Surg,2018,22(1):43-51.
[27] Shimizu H, Kimura F, Yoshidome H, et al.Aggressive surgical approach for stage Ⅳ gallbladder carcinoma based on Japanese Society of Biliary Surgery classification[J]. J Hepatobiliary Pancreat Surg,2007,14(4):358-365.
[28] Nigri G, Berardi G, Mattana C, et al.Routine extra-he-patic bile duct resection in gallbladder cancer patients without bile duct infiltration: A systematic review[J]. Surgeon,2016,14(6):337-344.
[29] Gani F, Buettner S, Margonis GA, et al.Assessing the impact of common bile duct resection in the surgical management of gallbladder cancer[J]. J Surg Oncol,2016, 114(2):176-180.
[30] Kurahara H, Maemura K, Mataki Y, et al.Indication of extrahepatic bile duct resection for gallbladder cancer[J]. Langenbecks Arch Surg,2018,403(1):45-51.
[31] NCCN. The NCCN clinical practice guidelines in oncology: hepatobiliary cancers (version 1.2019) [EB/OL]. Fort Washington: NCCN, 2019 [2018-12-17]. https://www.nccn.org/professionals/physician_gls/default.aspx
[32] Ostwal V, Swami R, Patkar S, et al.Gemcitabine-cisplatin (GC) as adjuvant chemotherapy in resected stage Ⅱ and stage Ⅲ gallbladder cancers (GBC): a potential way forward[J]. Med Oncol,2018,35(4):57.
[33] Keane FK, Zhu AX, Hong TS.Radiotherapy for biliary tract cancers[J]. Semin Radiat Oncol,2018,28(4):342-350.
[34] You MS, Ryu JK, Choi YH, et al.Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin[J]. BMC Cancer,2019,19(1):10.
[35] Arkenau H T, Martin-Liberal J, Calvo E, et al.Ramucirumab plus Pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase Ⅰ trial (JVDF)[J]. Onco-logist,2018,23(12):1136-1407.
